LONDON and NEW YORK, May 03, 2023 (GLOBE NEWSWIRE) — OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease (DED) to address the significant unmet need in this multi-billion-dollar market, today announced that two presentations will…Read More
OKYO Pharma Announces Presentations at the American Society of Cataract and Refractive Surgery ASCRS 2023 in San Diego CA May 58 2023
